Navigation Links
ClearWay Minnesota(SM) Adds New Director of Research

MINNEAPOLIS, Aug. 13 /PRNewswire/ -- ClearWay Minnesota announced today that Dr. Raymond Boyle, Ph.D., M.P.H., will be the new Director of Research for the organization. Dr. Boyle has training in Health Education and Epidemiology from the University of Oregon and the University of Minnesota.

"We are very excited about this new addition to ClearWay Minnesota and our research department," said David Willoughby, Chief Executive Officer of ClearWay Minnesota. "Dr. Boyle is well respected in his work on tobacco control and will help us continue to achieve our goals of reducing the harm of tobacco in Minnesota."

Prior to joining ClearWay Minnesota, Dr. Boyle was with the Department of Family Medicine and Community Health at the University of Minnesota Medical School. He has served as a research investigator for 10 clinical trials involving a wide variety of research topics including smoking and snuff cessation, weight loss among health plan members and adolescent health. In addition, Dr. Boyle has published more than 50 papers in peer-reviewed scientific journals.

About ClearWay Minnesota(SM)

ClearWay Minnesota is an independent, non-profit organization that improves the health of Minnesotans by reducing the harm caused by tobacco. ClearWay Minnesota serves Minnesota through its grant-making program, QUITPLAN(R) stop-smoking services and statewide outreach activities. It is funded with 3 percent of the state's 1998 tobacco settlement. For more information on ClearWay Minnesota or QUITPLAN Services, call 952-767-1400 or visit

SOURCE ClearWay Minnesota
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. ClearWay Minnesota(SM) Board Approves Four Regional Grants
2. ClearWay Minnesota(SM) Board Approves New Officers
3. ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobaccos Harm
4. ClearWay Minnesota(SM) Celebrates 10-Year Anniversary of Settlement
5. ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol
6. ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants
7. ClearWay Minnesota(SM) to Share Stories of Real Minnesotans Who Used QUITPLAN(R) Services During Great American Smokeout
8. Procter & Gamble Announces Appointment of Director
9. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
10. Jeff Korte Named as SIU Director, Litigation Solutions, LLC
11. Jim Deal Appointed to MedCaths Board of Directors
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: